Buy Ecstasy online in Richards Bay

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Buy Ecstasy online in Richards Bay

Official websites use. Share sensitive information only on official, secure websites. Borderline personality disorder is a complex psychiatric disorder with limited treatment options that are associated with large heterogeneity in treatment response and high rates of dropout. New or complementary treatments for borderline personality disorder are needed that may be able to bolster treatment outcomes. In this review, the authors comment on the plausibility for research on 3,4-methylenedioxymethamphetamine MDMA used in conjunction with psychotherapy for borderline personality disorder i. Borderline personality disorder is a serious psychiatric disorder with an especially high risk of suicide 1. Individuals with borderline personality disorder experience a substantial degree of impairment in psychosocial functioning 2 , and symptoms of the disorder cut across behavioral, affective, interpersonal, and cognitive domains 3. Clinical pharmacological findings suggest that no effective medication options exist to treat global borderline personality disorder symptoms 4 ; moreover, clinical guidelines advise that inpatient hospitalization for suicidality can increase rather than reduce the long-term risk of suicide among some patients with borderline personality disorder 5. Thus, clinical management poses unique challenges for health care providers, who, when surveyed, have reported that the chronic suicidality and interpersonal dynamics are the most challenging features of the disorder to manage 6 , 7. At present, many patients are referred to specialist treatments in which some wait times are years long because of a dearth of clinicians who are trained in specialist interventions, which typically range in length from 1 to several years. This backlog results in a revolving door of waitlisted patients who often present to the emergency department in suicidal crisis 8. Taken together, these facts depict the limitation of clinical resources available to mental health practitioners for stabilizing the prevalent and disabling presentation of those with borderline personality disorder. Although several evidence-based psychotherapies are effective for treating borderline personality disorder, there is large heterogeneity in individual treatment response and high rates of attrition 9 ; a recent systematic review has shown that almost half of patients prematurely drop out of treatment The largest bodies of evidence support the efficacy of mentalization-based therapy MBT and dialectical behavior therapy DBT for reducing self-harm and suicidal behavior among patients with borderline personality disorder 11 — Significant reductions in self-harm are often observed at 4—6 months into a treatment course 14 — 16 and sometimes earlier in a proportion of patients Although suicidal behavior is relatively slower to remit, a gradual decline has been observed extending into 1 year of specialist treatment In contrast, suicidal ideation often persists, even when suicidal behavior has remitted 11 , Regarding other borderline personality disorder symptoms e. The most recent Cochrane review of psychotherapies for borderline personality disorder also found that improvements in areas such as interpersonal functioning and fears of abandonment are small and no better than those observed in treatment as usual In tandem, naturalistic studies on the longitudinal course of borderline personality disorder symptoms have shown that relative to behavioral symptoms, the interpersonal and affective features of the disorder persist into later courses of the illness 19 — 21 ; this stage is also when death by suicide is more likely to occur among persons with borderline personality disorder 1 , Dependency-related interpersonal symptoms such as intolerance of aloneness and fears of abandonment appear especially persistent, even in samples in which the majority of participants have received individual therapy 19 , It is important to note that the enduring nature of interpersonal and affective symptoms in borderline personality disorder, along with the persistence of suicidal ideation, even alongside reduced suicidal behavior 11 , infers an ongoing suicide risk that is not adequately addressed by available treatments and may increase in the context of subsequent stressors. Specifically, interpersonal stressors are more likely to precipitate suicide attempts among persons with borderline personality disorder versus other disorders, with experiences of rejection and abandonment as highly potent antecedents 25 , Negative affectivity also appears to exert a strong moderating role on the association between interpersonal distress and suicidal behavior in borderline personality disorder 26 , Negative affectivity has been associated with the medical seriousness of suicide attempts 28 and other suicide-related processes in borderline personality disorder, such as reduced inhibitory control 28 and greater neurobiological reactivity to social exclusion These findings reflect the convergence across borderline personality disorder theories in their emphasis on the interpersonal 30 , 31 , the affective 5 , and, most recently, both the interpersonal and affective components of the disorder Taken together, borderline personality disorder is a complex disorder with limited treatments that do not appear to fully target the mechanisms by which interpersonal and affective features and by extension, suicidality and poor functioning are maintained. Thus, new or complementary treatments are needed that can address these gaps in treatment efficacy. In this review, we comment on the plausibility for research on 3,4-methylenedioxymethamphetamine MDMA used in conjunction with psychotherapy for borderline personality disorder i. Evidence is growing for the use of MDMA-AP as a promising treatment for various psychiatric conditions such as PTSD 33 , 34 and co-occurring eating disorder symptoms 35 , alcohol use disorder 36 , anxiety associated with life-threatening illness 37 , and social anxiety in autism spectrum disorder It is important to note that in contrast to traditional pharmacological treatments in psychiatry, which often entail taking a psychotropic medication daily for an indeterminant amount of time, MDMA, when used as an adjunct to psychotherapy, has been shown to be clinically efficacious when administered two to three times during a treatment course MDMA is a phenethylamine compound that is structurally similar to methamphetamine and mescaline and produces psychostimulant effects. In the late s, the American chemist Alexander Shulgin resynthesized the compound and shared it with a close colleague and psychotherapist Leo Zeff. It was then disseminated to a growing number of clinicians who observed its therapeutic potential in individual, couples, and group psychotherapy settings 42 ; however, in , the U. Drug Enforcement Administration declared it a schedule I substance, making its use illegal. For a review of the pharmacological mechanisms of MDMA, we refer readers to available resources 40 , It is important to contrast uncontrolled recreational use of MDMA with controlled use in clinical research settings. In the recreational setting, although medical toxicity i. The most common adverse events related to MDMA administration in research settings include elevated heart rate and blood pressure, muscle tightness, bruxism, decreased appetite, nausea, hyperhidrosis, and feeling cold 48 , Regarding addictive liability, recreational MDMA use is substantially less likely to produce dependence syndromes, especially compared with other dopaminergic stimulants i. Given its safety profile, the risk-benefit ratio is favorable for the use of MDMA in the treatment of chronic and severe psychiatric disorders that are often associated with a substantially increased risk of death e. Compared with each individual disorder alone, comorbid borderline personality disorder and PTSD is also associated with higher comorbidity of additional psychiatric disorders 54 , greater symptom severity 55 , more self-harm and suicidal behaviors 55 , 56 , and higher utilization of mental health and emergency services Given their overlap, a brief review of shared phenomenological features and neurobiological substrates of borderline personality disorder and PTSD is presented to contextualize a discussion of treatment targets for MDMA-AP for borderline personality disorder. Borderline personality disorder is a stress-related disorder often associated with a history of adverse and traumatic experiences going back to childhood 58 , It is not well understood how chronic stress or traumatic exposures might lead to the manifestation and severity of borderline personality disorder or PTSD or their co-occurrence ; indeed, their nosology has been the subject of long-running debate among clinicians and researchers in the fields of personality and traumatology For example, Martin Bohus has put forth the view that borderline personality disorder is linked to past traumatic experiences and perhaps would be better classified as a trauma- and stress-related disorder However, even when conceptualizing borderline personality disorder as a distinct nosological entity, most seminal theories emphasize a strong association between traumatic or disturbed early attachment experiences and subsequent borderline personality disorder symptoms appearing more conspicuously during adolescence 61 , Bender and Skodol 64 further posited that early experiences of trauma and invalidation are the fundamental causes of self-interpersonal disturbances in borderline personality disorder. Some proponents of this diagnosis argue that complex PTSD is an amalgam of borderline personality disorder and PTSD 66 , whereas others propose that borderline personality disorder alone should be rebranded to complex PTSD 67 , Still, others advise that borderline personality disorder should remain a separate diagnostic entity from complex PTSD Relatedly, although it is less clear how neurobiological underpinnings translate to symptomatology e. Amad et al. This gene is an important regular of the glucocorticoid receptor complex 74 , 75 , and this receptor complex plays a role in the dysregulation of the HPA axis observed in both disorders 76 , The authors also noted that both disorders share functional abnormalities in frontolimbic networks, particularly in reduced activation of executive-related frontal brain regions, a hyperactivation of the emotion-related limbic regions 73 , 78 , 79 , and an increased activation in the superior and inferior frontal gyri areas involved in attention, working memory, and response inhibition. Additionally, reduced hippocampal and amygdala volumes compared with healthy control groups have been observed among patients with either disorder Although an in-depth critical examination of these diagnostic constructs is beyond the scope of this review, it is important to appreciate the significant degree to which research findings support the hypothesis that trauma plays a role in the development and manifestation of borderline personality disorder. Several studies have demonstrated that trauma is a strong predictor of the disorder 81 — 83 and its associated social cognitive impairments The conceptual and phenomenological similarities between borderline personality disorder and PTSD are also substantial; they include impairments in social cognition and self-concept, interpersonal difficulties, affect dysregulation, and dysregulated stress responses such as dissociation 66 , 72 , Moreover, research that contributed to the recently developed Hierarchical Taxonomy of Psychopathology HiTOP , a dimensional classification model, provides empirical support for shared traits across borderline personality disorder and PTSD within the domain of internalizing distress e. Given the many similarities between the two disorders, it is plausible that adaptations to early traumatic invalidation i. Zeifman and Wagner 90 have proposed various borderline personality disorder treatment targets that psychedelic and related substances, including MDMA, may affect, such as behavioral and emotional dysregulation, self-identity disturbances, and social functioning. Given the theoretical associations between early attachment disruptions and borderline personality disorder symptoms 61 — 63 , we suggest that targeting interpersonal and affective symptoms may be realized in MDMA-AP for borderline personality disorder by focusing on processing traumatic invalidation or trauma. These findings are also consistent with a smaller trial of MDMA-assisted cognitive-behavioral conjoint therapy for PTSD, which found improvements in emotion regulation and relationship functioning 91 , Notably, these long-term improvements also converge with dimensional models of personality psychopathology that propose that disturbances in self i. Thus, it is reasonable to speculate that similar functional improvements may be observed in MDMA-AP for borderline personality disorder, although this hypothesis requires empirical study. Moreover, researchers have also found MDMA-AP—related changes in personality structure by way of decreased neuroticism and increased openness 95 , which are two personality traits shown to have significant genetic correlations with borderline personality disorder in a recent study Plausibly, decreased neuroticism and increased openness could help to loosen the rigid self-other beliefs and schemas e. We hypothesize that mechanisms of change in MDMA-AP for borderline personality disorder may include reduced avoidance of emotions that are activated by thinking or talking about difficult experiences related to traumatic invalidation and trauma as well as increased willingness to disclose covert experiences to therapists e. It is plausible to speculate that these mechanisms would be catalyzed by the acute effects of MDMA, which are predominantly attributed to its activation of the serotonergic system, and include improved mood, reduced fear-related amygdala reactivity 46 , and reduced aggression and impulsivity Moreover, a recent animal study showed that a single dose of MDMA was able to reopen an oxytocin-mediated critical period of social reward learning Mithoefer et al. Although the activation of such networks may normally provoke strong emotional reactivity or maladaptive avoidance and defenses that can interfere with therapy, these reactions may be held at bay under the acute effects of MDMA. This consequence may be especially helpful to reduce emotional oscillations and interpersonal reactivity that are observed in borderline personality disorder and that can be associated with highly treatment-interfering behaviors e. Initial evidence to suggest that these mechanisms may improve borderline personality disorder outcomes can be derived from Barnicot et al. This finding is also consistent with a recent meta-analysis showing associations of experiential avoidance with self-harm and suicidal ideation Moreover, oxytocin, a neurohormone released by MDMA, was administered in two large, placebo-controlled studies of borderline personality disorder , Lischke et al. Similarly, in their double-blind, placebo-controlled study, Domes et al. These findings mirror two other studies showing an attenuating effect of oxytocin on amygdala responses to angry faces and dysphoric mood among individuals with borderline personality disorder Although, another research group found reduced trust and cooperation following oxytocin administration among patients with borderline personality disorder Thus, although oxytocin is a potential mechanism that could subserve MDMA-AP—related improvements, its effects on individuals with borderline personality disorder are not clear and require further study. With the therapy targets and hypothesized mechanisms described earlier in mind, this review concludes with several initial clinical research considerations pertaining to the design of MDMA-AP clinical trials to test the safety, feasibility, and initial clinical effects of MDMA-AP for borderline personality disorder. Briefly, MDMA-AP involves at least one preparatory session in which therapists work with patients to plan for the dosing session, including discussions around safety, expectations, intentions, and coping with anticipated difficulties or psychological tendencies that may arise during the dosing session e. An MDMA dosing session lasts around 8 hours and involves two therapists who support and guide a patient through the MDMA experience, typically in a nondirective fashion while the patient is laying down, wearing eye shades, and listening to music to promote immersion into the experience One or more psychotherapy sessions follow the dosing session often referred to as integration sessions and focus on helping the patient to gradually reflect on and process i. To aid in this focus, psychoeducation may be provided before MDMA dosing sessions so that patients can identify and tie together salient past experiences and current problem behaviors e. Although two to three doses 80— mg of MDMA are typically given throughout a course of MDMA-AP, case studies and pilot trials would be helpful to explore optimal MDMA dosage, dosing frequency, and dosing intervals for patients with borderline personality disorder. Relatedly, studies are needed to explore the cost-effectiveness of MDMA-AP for borderline personality disorder, relative to first-line specialist treatments e. Despite the potential of MDMA-AP for treating borderline personality disorder, some unique risks warrant careful consideration. First, although no deaths by suicide have been reported across phase 2 or 3 MDMA-AP for PTSD clinical trials 34 , 48 , chronic suicidal behavior is a symptom of borderline personality disorder 3 ; thus, suicide risk management is of paramount importance. Relatedly, because impulsivity and anger dysregulation are also symptoms of borderline personality disorder, the development of a safety plan, especially for patients with a history of impulsive aggression, is prudent. In particular, individuals with borderline personality disorder are highly sensitive and reactive to negative affect 5 , which can be heightened during the MDMA experience and as the acute effects of the drug wear off. Given associations of negative affect with both suicidal behavior 26 , 27 and impulsivity among patients with borderline personality disorder 28 , several risk management strategies may be considered. For example, given the particular effectiveness of DBT and MBT for treating self-harm and suicidal behavior among patients with borderline personality disorder, a phase-based treatment approach to MDMA-AP could be used to reduce, eliminate, or place contingencies around self-harm and suicidal behavior using relevant treatment strategies. Following risk assessment and planning, MDMA preparation, dosing, and integration sessions may be incorporated at strategic windows throughout the treatment course, with the dosing session facilitated in a controlled environment Behavioral strategies, such as contingency management, reinforcement and shaping, and creating a safety plan to cope with self-harm and suicidal urges, may also provide beneficial structure in which MDMA-AP may be effectively practiced with patients with borderline personality disorder. Additionally, similar to the structure of interventions for comorbid borderline personality disorder and PTSD in which patients are taught skills to support adequate experiential immersion into exposures 89 , skills to cope with avoidance behaviors, impulsive urges, suicidal ideation, and dissociation e. Alternatively, given the length of specialist treatments for borderline personality disorder, a more generalist approach could also be used in conjunction with MDMA-AP; for example, good psychiatric management is an approach that has been found to be as efficacious as DBT for borderline personality disorder in a previous clinical trial Finally, as in standard DBT, patients may have access to on-call phone coaching for help using skills to cope with difficult experiences including suicidal ideation and negative affect that may arise after the experience and before their integration session, which is typically scheduled for the day following the MDMA session. Moreover, because the acute effects of MDMA can promote strong feelings of connectedness and increased disclosure of difficult experiences, patients are more vulnerable and may become very attached to therapists or experience stronger transferences. As such, boundary considerations are an important aspect of treatment planning. In the context of borderline personality disorder symptomatology, it is possible that strong feelings of idealizing and abandonment sensitivity may arise. To anticipate this possibility, we suggest that discussions about relationship boundaries should occur during MDMA preparation. For example, boundaries around physical touch e. Importantly, Williams et al. Among other steps, the authors discussed the importance of assessing for racial trauma, thoughtful research advertising and selection of dosing session music, fair compensation of participants for their time and travel, and ensuring that the research team includes therapists of color. MDMA-AP is a novel, experimental intervention, and it is crucial to examine whether it is efficacious for people of color, who are grossly underrepresented in clinical research studies. Additionally, given the strong potential for placebo effects to be heightened in the context of a highly novel, biological intervention, after the initial safety and feasibility of MDMA-AP for borderline personality disorder are examined, researchers should ideally use randomized, double-blind, placebo-controlled trials — Lastly, because the majority of treatment-seeking individuals with borderline personality disorder are women , the generalizability of research findings to other genders has been limited; thus, more targeted recruitment of gender-diverse samples in future work is crucial. For example, recent research has suggested that compared with women, men with borderline personality disorder have poorer top-down control of aggression , suggesting that treatment targets for men with borderline personality disorder may differ from those of women. In summary, MDMA may have potential to improve treatment outcomes for individuals with borderline personality disorder. In particular, we hypothesize that the acute effects of MDMA may promote reduced emotional avoidance and support the development of a strong therapeutic rapport associated with disclosure of important therapeutic material, catalyzing more fulsome processing of traumatic invalidation or trauma. These hypothesized mechanisms may support shifts in the attachment-related structures that play a role in persistent areas of dysregulation and dysfunction among patients with borderline personality disorder, such as interpersonal and affective symptoms and related suicidal tendencies. Roberts has received compensation as an independent contractor for his role as an assistant trainer from Fluence. Ross is a coinvestigator on the MAPS MDMA-assisted psychotherapy for posttraumatic stress disorder phase 3 trials; he also reports research support from Usona and Reset Pharmaceuticals related to psilocybin research, two patents with Reset, and funding from the National Institute on Drug Abuse. Zeifman has received compensation as an independent contractor for the role of study therapist on a MAPS-funded clinical trial of MDMA-assisted psychotherapy. None of the aforementioned organizations were involved in the design, execution, interpretation, or communication of findings of this publication. As a library, NLM provides access to scientific literature. Focus Am Psychiatr Publ. Find articles by Jenna M Traynor. Daniel E Roberts , M. Find articles by Daniel E Roberts. Stephen Ross , M. Find articles by Stephen Ross. Richard Zeifman , M. Find articles by Richard Zeifman. Lois Choi-Kain , M. Find articles by Lois Choi-Kain. Traynor jtraynor1 partners. Issue date Oct. Similar articles. Add to Collections. Create a new collection. Add to an existing collection. Choose a collection Unable to load your collection due to an error Please try again. Add Cancel.

The Ecstasy and the Agony

Buy Ecstasy online in Richards Bay

Apply today. Over Psychiatrists and other clinicians have been trained with us. This program is both for prescribing psychiatrists, as well as other mental health professionals who will be delivering the treatment as part of a multidisciplinary team. The training is delivered by a world-class faculty made up of global leaders in the field. These are the three psychedelic medicines with regulatory approval in Australia. Apply now to secure your spot for the February Intake. Financial Assistance places are available for those who can display excellence, need and commitment. Psychedelic-assisted therapies PAT are delivered by treatment teams with three main roles: prescriber, primary therapist and secondary therapist. This course has been developed to address the training needs for the three roles, recognising the desirability of members of PAT teams to understand the entire PAT treatment process and the roles each assumes. The Certificate in Psychedelic-Assisted Therapy course provides appropriately qualified and experienced healthcare professionals with the necessary capabilities, knowledge and skills to safely and successfully facilitate PAT in a clinical environment, in accordance with their role as prescriber, or primary or secondary therapist. Please note: Psychiatrists are responsible for prescribing psychedelic medicines. However, they work as part of a multidisciplinary team including other mental health professionals to deliver treatment. This world-class training program is suitable for both prescribers and therapists. Prescribers: For those who have the necessary qualifications to prescribe psychedelic medicines, this course will equip them with the knowledge and skills to create and document a PAT treatment protocol, and safely prescribe specific psychedelic medicines for specific mental health conditions. Therapists: The course will prepare appropriately qualified and experienced healthcare professionals with the skills and knowledge necessary to safely and effectively support patients undergoing PAT as primary or secondary therapists. Note that the ability to practice as a primary therapist in PAT is also dependent on prior relevant clinical experience in psychotherapy. The course includes a combination of face-to-face and online learning and self-study. It is delivered over 13 weeks of online learning and a 6-day full-time, face-to-face residential workshop. The main psychedelic medicines this course focuses on are MDMA, psilocybin and ketamine. Training of prescribers and therapists occurs together, reflective of the holistic team approach that characterises PAT. In previous iterations of the course, learners have given positive feedback specifically about the value of training together. However, whilst the curriculum is the same for all learners enrolled, in recognition of the unique roles and levels of responsibility of prescribers and therapists, assessment tasks differ for prescribers and therapists and serve to differentiate the CPAT award into two distinct awards: the CPAT-Prescriber and the CPAT-Therapist. Only psychiatrists and medical practitioners will be eligible to complete the assessment for Prescribers and be awarded the CPAT-Prescriber. Her early biological and research background includes a completed fellowship in clinical psychopharmacology and neurophysiology at New York Medical College and a research fellowship at NYU Medical Center. She has a special interest in teaching interview technique, psychoanalytic theory and British object relations. Dr Vaid is a leader in ketamine assisted psychotherapy which she practices and teaches in New York City. She serves as a lead instructor at The Ketamine Training Center with psychedelic psychotherapy pioneer, Dr. Phil Wolfson. She is a co-founder of the Center for Natural Intelligence, a multidisciplinary laboratory dedicated to psychedelic psychotherapy innovation and research. Deepak Chopra is currently developing protocols integrating meditation with ketamine assisted psychotherapy. Vaid G, Walker B. Glob Adv Health Med. The bestselling author of five books published in nearly 40 languages, including the award-winning In the Realm of Hungry Ghosts: Close Encounters With Addiction, Gabor is an internationally renowned speaker highly sought after for his expertise on addiction, trauma, childhood development, and the relationship of stress and illness. Eli is a consultant psychiatrist and psychodynamic psychotherapist. Eli completed the inaugural CPAT course, and has since been on its faculty. As an adjunct lecturer at Monash University, he oversees medical students on their addiction medicine rotation, and sneaks in lectures on Philosophy of Mind, Psychodynamic Psychiatry and Psychedelic Assisted Therapies PAT. He has been invited by the Victorian Government to design new addiction programs and works with the AFL players association. He also has extensive research experience with novel therapeutics for neurodegenerative diseases. He sits on the Victorian Medical Panels, and is an expert witness in historical abuse cases. Clinically, Eli works in a psychodynamic framework, and attempts to help his patients find freedom from their addictions and trauma through relational experiences, and experiential self-awareness. Dr Bessel van der Kolk MD, Professor of Psychiatry, Boston University School of Medicine and President, Trauma Research Foundation, has spent his career studying how children and adults adapt to traumatic experiences, and have tried to translate emerging findings from pharmacology, neuroscience and attachment research to develop and study potentially effective treatments for traumatic stress in children and adults. He conducted the first studies on the effects of SSRIs on PTSD; he was a member of the first neuroimaging team to investigate how trauma changes brain processes, and he did the first research linking BPD and deliberate self-injury to trauma and neglect in early childhood. His seminal book The Body keeps the Score , has been on the New York Times best seller list for over weeks, and has been translated into 42 different languages. She is a psychiatry doctor, psychedelic therapy guide and group facilitator. For the last few years she has been a clinical trial doctor at The Centre for Psychedelic Research Imperial College London investigating psilocybin-assisted therapy for anorexia-nervosa, chronic pain, and treatment-resistant depression. Alongside her clinical roles Lauren regularly facilitates psilocybin retreats in The Netherlands, and is co-founder of Essence Medicine, an organisation providing psycho-spiritual group support to people facing life threatening illness. Lauren is also passionate about educating future psychedelic facilitators and delivers integrative, experiential and heart-centred training for Mind Medicine Australia and PsyEdu UK. Lauren has trained in medicine, psychology, MDMA-assisted therapy, and yoga, and continues to be a student of earth-based, indigenous wisdom traditions. She is driven to help people come home to themselves, unfold more of who they truly are, and deepen into the beauty and mystery of life. Rabbi Tirzah Firestone, Ph. Widely known for her groundbreaking work on Kabbalah, depth psychology, and the re-integration of the feminine wisdom tradition within Judaism, Rabbi Tirzah lectures and teaches internationally about spiritual and ancient wisdom practices that are honed to assist us at this critical time in world history. Professor David Nutt is a renowned researcher, policy advisor and author, who is currently Head of Neuropsychopharmacology at Imperial College London. Professor Nutt has also held many leadership positions in both UK and European academic, scientific and clinical organisations, including presidencies of: the European Brain Council, the British Neuroscience Association, the British Association of Psychopharmacology, the European College of Neuropsychopharmacology. Dr James Fadiman B. Harvard M. Stanford began his personal psychedelic research a few weeks before starting his graduate work at Stanford where he did his dissertation on the effectiveness of LSD-assisted therapy. During the research lull of 40 years, he has held a variety of teaching San Francisco State, Brandeis, and Stanford consulting, training, counseling and editorial positions. He has taught in psychology departments, design engineering, and for three decades, at the Institute of Transpersonal Psychology now Sofia University that he co-founded. James has published textbooks, professional books, a self-help book, a novel, and a series of videos, Drugs: the children are choosing for National Public Television. His books have been published in 8 languages. He has been the subject of a one-hour documentary released by Page3 Films, featured in a National Geographic documentary and had three solo shows of his nature photography. James had his own consulting firm and sat on two non-profit boards as well as having been the president of several small natural resource companies. He has been involved in researching psychedelic for spiritual, therapeutic and creative uses and is known for his pioneering work on microdosing. The book he is writing now has the working title All About Microdosing. Rick Doblin, Ph. His undergraduate thesis at New College of Florida was a year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. Rick studied with Dr Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in , and currently resides in Boston with his wife and empty rooms from three children who are all in college or recently graduated. Dr William A. David Erritzoe is a psychiatrist and neuroscientist. He holds a Clinical Senior Lectureship i. He has authored more than peer-reviewed scientific papers and 4 book chapters. His clinical practice with ketamine has informed his leadership role in the development of Ketamine Assisted Psychotherapy. He has been awarded five patents for unique herbal medicines. He is a journalist and author of numerous articles on politics, transformation, psychedelics, consciousness and spirit, and was a founding member of the Heffter Research Institute. She is a somatic educator, artist, singer-songwriter, and bodyworker who works with traumatized individuals and trains mental health professionals to use mindful meditation in movement, theater exercises, writing, and voice as tools for attunement, healing, and connection. For the past decade, she has been teaching expanded awareness in workshops to clinicians and laypeople around the world. Bianca King M. She is co-founder with psychiatrist Dr. She has been prominent in the Geneva community for running mindfulness courses for the public, the UN, and International organizations. Throughout her life, Bianca connected with the practice of vipassana meditation and travelled to Asia to participate in teachings and retreats. She found she was learning about a dimension of the human experience that complimented her education and training in psychotherapy and psychology. For her Masters in Psychotherapy and Counselling through the University of Wales, Bianca concentrated on existential issues as she found her heart was in the work of hospice and palliative care that she had originally experienced at the Petrea King Quest for Life Foundation. His work focuses on novel paradigms of drug action at G protein-coupled receptors, the largest drug-target class for current medicines, and has been applied to fundamental and translational studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes and chronic pain. Professor Christopoulos has over publications, including in leading journals such as Nature, Science and Cell. He has also been the recipient of multiple major national and international awards. After obtaining her MD degree in at the University of Geneva medical school, Julia completed four years of residency training in Internal Medicine at the University Hospital of Geneva, before opting to specialize in Psychiatry. Julia uses an integrative approach drawing from a wide range of psychotherapeutic models in her practice Freudian psychodynamic theory, Compassion Focused Therapy, EMDR and Mindfulness approaches. She also facilitates two-part ecopsychiatry workshops in natural settings, combining Shinrin Yoku Japanese forest bathing with Breathwork. The center provides innovative and legal psychedelic assisted therapy to Swiss residents who meet the compassionate use criteria of the Swiss Department of Public Health. She completed the five-part certification in MDMA assisted psychotherapy in Dr David E. Previously he held the Robert C. He received his B. In he was named the Irwin H. He has published more than scientific articles, most of which deal with the relationship between molecular structure and biological action. Jeff Leifer is an impact advisor and educator in the Psychedelic Medicine space. He is the founder of Circadian, a cross-sector collaboration and experience lab building engaged, resilient communities and presenting powerful voices in the fields of innovative mental health and the study of consciousness. Jeff also serves on the advisory board for Anuma, exploring digital group therapeutics that combine virtual reality VR with the science of psychedelics. Jeff leads the Psychedelic Listening Project, which documents diverse views on the state of the psychedelic ecosystem to inform best practices for philanthropists. The project will inform stakeholders looking beyond traditional funding approaches, prioritizing models that encourage human flourishing and shared decision-making. Jeff has also worked extensively with Indigenous communities in the Global South to support the embodiment of plant medicine lineage, traditional ecological knowledge and forest-based, economic resiliency. Prior to launching Circadian, Jeff thrived in the world of social finance, pioneering capital reforms, collaborative governance and public finance accountability. She has spent her early career examining ways culture informs how we diagnose and treat mental illnesses. Sara has participated as a study therapist and participant in psychedelic therapy research and is currently the lead study therapist at Imperial College London for their psilocybin for OCD trial. She lectures on topics fusing culturally sensitive practices within psychedelic-assisted therapy and advises organizations on anti-oppressive and inclusive practices. Trees, a Goori Dhanggati woman and GP, is a dedicated healthcare professional, often serving as the sole doctor in remote areas of Western Australia and the Northern Territory, particularly within Aboriginal communities and islands. Trees initially trained in Traditional Chinese Medicine as an acupuncturist before pursuing science. Trees continues to champion Indigenous values within educational systems. Beyond her medical career, she excels as an award-winning novelist in Magical Realism and Speculative Fiction. Namae has been exploring altered states of consciousness and working with plants, herbs, fungi, shamanic breathwork and experiential spiritually transformative modalities for over 30 years. Her innovative and feminine approach combines ancient spiritual practices, indigenous and mystical lineages with therapeutic counseling, tantric embodiment, artistic expressions, scientific knowledge, neurobiology, biomimicry, and ecology. She has created tools of deep transformation, shamanic ceremonies, and rituals that help people connect, love, and attain awareness in altered states, supporting their integration and to adapt to subtle and dynamic changes in their lives, to become more whole, and to re-embed themselves in the spiritual potency of Nature. Namae is also a designer and teacher of a 3-year facilitator training curriculum, Guide of the Heart, as well as training modules to teach facilitators how to guide from love, and connect people to the intelligence of Life. She led spiritual adventure tours to Peru, Bolivia, Australia, and other locations in the States, working with indigenous healers, mystics, shamanic practitioners, spiritual guides, and teachers. She has danced and taught the feminine path of tantra, lived the life of a pantheanic hermit for several years in the forests of Maui, explored the nature of consciousness and played with many artistic expressions. Namae is deeply devoted to the awakening of Love through direct relationship with the intelligence of Life. Ashleigh has co-designed the ARC ethics framework with Dr. Meg Spriggs and colleagues to support the development of safe and ethical practice guidelines in psychedelic-assisted therapies. Ashleigh has also led a psychedelic integration group to help people access therapeutic and community-based peer support after having beneficial or challenging psychedelic experiences. Ashleigh is trained to work flexibly with psychodynamic, systemic, cognitive-behavioural and mindfulness-based therapies. Since , Francoise has apprenticed with shamans and healers in the U. In the last 25 years, she has traveled with groups to Mexico, incorporating her counseling practice experience with her knowledge of expanded states of consciousness where she partners with Mazatec healers in Sacred Mushrooms ceremonies. She also leads workshops and contributes to conferences internationally. Her book, Consciousness Medicine is available everywhere books are sold. Here she has a private practice as a Mental Health Social Worker working somatically, with nature, in trauma-focused care and the integration of experiences. Trudi has worked for over 25 years with expanded states of consciousness through birthwork and earth connection practices. Trudi is active in the Deep Ecology and Wayapa Wuurrk networks as a practitioner, facilitator and trainer and runs sessions, group work, workshops and retreats. Her work is anchored in experiencing pieces that remind us of how we need to nurture ourselves, each other and Country, which has the potential to ignite deep earth, mind, body and spirit connections to what is missing. She is called to this position within her work to support others to discover and rediscover this connection in times that are changing — and that there are many ways we can work with and hold space for expanded states of consciousness to find meaning. She is on a joyous quest of exploring the felt sense of connection out there in the world! She regularly presents on psychedelic-assisted therapies, mental health and wellbeing at major conferences and events around the world and to Governments, regulators, clinicians, philanthropists and the general public. As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. He regularly presents to Governments, regulators, clinicians, philanthropists and the general public on psychedelic-assisted therapies and the legal and ethical frameworks needed to ensure these treatments can be made accessible and affordable. Submit your application. Not only have I been blessed with making what I think will be lifelong friendships, but I have grown both personally and professionally beyond what I could ever have expected. Thank you! I am so excited to be at the forefront of this 'renaissance' of plant medicines and truly believe that they will offer hope and a way forward to many who have felt disheartened with current mental health treatments. It puts the participant through a journey as well. Change is not only individual. It is not only in groups. It is all of the above. And more. Having attended over thirty different workshops, and PD of all sorts. To the facilitators and teachers: there are honestly not enough sufficient words to express my gratitude and appreciation to you! Psychedelic medicine is here; learn about it and you will not only understand it better, but it may reinvigorate your career. A must for anyone interested in challenging their preconceptions and offering something new to their patients. Delivered by a world class faculty and thoroughly recommend. Not only were we given all the education and skills to do this work, but we were also given the deep exposure into psyche, to ensure that we do it with compassion, professionalism, and reverence. I feel that my understanding of the medicine has improved and the course has prepared me to both sit with patients on the medicine and to help them integrate their experiences. I would highly recommend this course to other practitioners interested in this emerging science. This world suffers from a huge PTSD and needs this so much. Thank you. The content was so well put together and delivered by extremely professional presenters. Ben and Lauren were completely amazing. The breathwork was the highlight of my experience. I went into the session with a lot of anxiety but felt completely safe and held by both my sitters and the facilitator. Craig and Maurizio have an incredible presence and skill at creating a safe container. Overall, I would strongly recommend anyone thinking of doing the course to jump in and expand your mind and heart. Thank you all. This was such a mind-expanding, heart-opening experience. If you are curious follow your instinct, enrol, and enjoy the journey! I am grateful for having done the course. It answered many questions and the whole experience was educational. MMA made learning fun. Download the testimonials from our previous intakes: Download pdf It may also form the basis of individual professional development and training plans. All our training courses and events can also be used to claim ongoing Continuing Professional Development CPD points in Australia through professional colleges e. Please check with your professional membership body for the appropriate category and number of points. Note that this is not an entry level course that qualifies an individual to practice psychotherapy. Applicants are expected to already be qualified to practice in the mental healthcare field and have relevant clinical experience. Preference will be given to applicants who have clinical experience in mental healthcare. Applicants who do not work in one of the above professions will be considered if they:. B have substantial experience in altered state based work in non-clinical environments such as breathwork practitioners, indigenous healers, shamanic practitioners. Please note that those from the above categories will receive a certificate of participation in place of a CPAT-prescriber or CPAT-therapist certificate of completion. Start your application. Mind Medicine Australia has donated funds to The Australian National University ANU to enable them to conduct a study of brain activity associated with exposure to psychedelics including MDMA and psilocybin in people who have completed training in psychedelic assisted psychotherapy. FAQs Apply now. If you have further questions please contact MMA. Each week of the online course has a 3-hour class, with additional readings, experiential workshops and discussion exercises to support your learning. After receiving your application it will be reviewed within 3 business days. Admission interview times will be shared for applicants who meet the eligibility criteria that you can book within the following weeks. We review interviews at the end of each week. After you complete your admission interview you will be notified by the end of that week with an outcome. Payment in full or the first instalment will be required within 7 business days following an offer. Live attendance is not required for online sessions. We strongly encourage all students to attend as many sessions live as they can and ask questions and engage with the teachers and other students. All sessions will all be recorded for later viewing for those who cannot attend. Prescribers and therapists complete the training together. All content is completed by all students. This structure ensures that all clinicians seeking to work in PAT have a foundational understanding of all areas relevant to delivering these treatments. Note that prescribers who are also suitably trained to deliver therapy such as psychiatrists will be able to work as both a prescriber and a therapist upon completion of the course. MMA has found that a diverse, multidisciplinary group of professionals significantly enhances the learning experience. It also leads to a strong network of life-minded professionals who often form clinical groups, networks and teams following the course. Ketamine-assisted psychotherapy KAP has less regulations around who can work to deliver treatment. As PAT is a new and developing field, the accreditation standards and structures have not yet been in place to begin accrediting training programs. MMA is actively working with the Australian and international educational and other organisations to support further accreditation of the course as it becomes possible to do so. Some financial assistance is available on a competitive basis. Apply for consideration now. Applications open: Are open for intakes applicants will be considered in order of receipt. We expect the program to be over-subscribed so please register early to avoid disappointment. Step 2: Applications will be screened, and if successful invited to an interview. These are self-scheduled via our online portal. Step 3: If successful in your interview, you will be invited to join the course. Your place in the course will be secured upon receipt of your signed student agreement and your first payment. Please use the contact form below to get in touch. Alternatively, send us an email to cpat mindmedicineaustralia. Apply now for our next intake beginning in February. Applications for February intake close on November Places are filling fast. We also strongly recommend applying for July intake asap. Are you interested and ready to learn more? Access free information pack. Close panel. Old Age Psych. D Website. Bianca King Switzerland M. Namae Ntumae USA. Trudi Hayes AUS. Peter Hunt AM B. Com, LL. B LinkedIn profile. Course structure and contents. Course accreditation. You will be taken to the PayPal site upon completion of the application form. MMA will issue your invoice s for remaining course fees upon acceptance into the course. Cost of the course includes: World-class program, developed in conjunction with leading international program First in Australia and the Asia-Pacific region Taught by international leaders and top Australian experts 75 hours of live face-to-face and webinar teaching Additional reading and teaching material supporting tuition One weeklong residential intensive. Accommodation and meals included. Residential week provides direct, personalised skill development and practical exercises, assessment and risk management skills. Monitoring of skill development through on-going evaluation and coursework Therapists learn skills for working in different settings: research programs, individual psychedelic therapeutic interventions within medical settings for a range of mental illness conditions, and the provision of psychological therapy and integration work outside of these settings. Contact us.

Buy Ecstasy online in Richards Bay